AlphaCentric Advisors’s Yarrow Bioscience YARW Stock Holding History

AlphaCentric Advisors’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,370	Closed	-$505K	–	286
2024 Q3	$505K	Sell	5,370 -840	-14%	-$79.6K	0.38%	74
2024 Q2	$612K	Sell	6,210 -2,690	-30%	-$335K	0.45%	71
2024 Q1	$1.37M	Sell	8,900 -4,463	-33%	-$481K	0.82%	47
2023 Q4	$1.56M	Buy	+13,363	New	+$2.08M	1.05%	32

Other funds holding YARW

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

EAM

Exome Asset Management New York $162M AUM 259.04% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

AlphaCentric Advisors's YARW Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Yarrow Bioscience (YARW) in Q4 2024, closing a stake of 5,370 shares — an estimated $505K sold.

AlphaCentric Advisors first reported a position in YARW in Q4 2023 and held it in 4 quarters. The position peaked at $1.56M in Q4 2023. 34 funds tracked by Wall St. Rank hold YARW as of Q4 2024.

AlphaCentric Advisors reported no remaining Yarrow Bioscience position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 5,370 Yarrow Bioscience shares in Q4 2024, an estimated $505K.
AlphaCentric Advisors first reported a position in Yarrow Bioscience in Q4 2023 and held it in 4 quarters.
AlphaCentric Advisors's Yarrow Bioscience position peaked at $1.56M in Q4 2023.
34 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.